Protecting Your Products and Brand Online
PODCAST: Williams Mullen's Trending Now: An IP Podcast - Cease and Desist Letters: Protecting Your Intellectual Property the Right Way
What Were the Cooler Wars? (Part 2) — No Infringement Intended Podcast
What Were the Cooler Wars? (Part 1) — No Infringement Intended Podcast
PODCAST: Williams Mullen's Trending Now: An IP Podcast - IP and M&A Transactions
AGG Talks: Cross-Border Business Podcast - Episode 20: Mastering ITC Section 337 Investigations
3 Key Takeaways | What Corporate Counsel Need to Know About Patent Damages
Patent Litigation: How Low Can You Go?
(Podcast) The Briefing: Netflix to Pay $2.5M to GoTV for Patent Infringement
The Briefing: Netflix to Pay $2.5M to GoTV for Patent Infringement
The Art of Teaching Complex Technology in Patent Litigation - IMS Insights Podcast Episode 67
The Briefing: Failure to Disclose Relationship with Real Party in Interest Results in Serious Sanctions
Podcast: The Briefing - Failure to Disclose Relationship with Real Party in Interest Results in Serious Sanctions
5 Key Takeaways | How to Effectively Leverage the Chinese Patent System
Estoppel Doctrine in China's Patent System
Donation (Disclosure-Dedication) Doctrine in China’s Patent Litigation
6 Key Takeaways | Patent Opinions – New Developments and Pitfalls
Patent Right Evaluation Report in China’s Patent System
Kidon IP War Stories: David Cohen & Daryl Lim
Protecting the PB&J – Preserving IP Rights from Concept to Market
In Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. v. Sirius XM Radio Inc., No. 1:17-cv-00184-JFB-SRF (D. Del. Mar. 24, 2026), the U.S. District Court for the District of Delaware held that Sirius XM...more
On April 16, 2026, the U.S. Court of Appeals for the Federal Circuit (the court) issued a precedential decision in Teva Pharmaceuticals International GmbH v. Eli Lily and Company, determining that the claims of Teva’s U.S....more
Our Patent Case Summaries provide a weekly summary of the precedential patent-related opinions issued by the Court of Appeals for the Federal Circuit and the opinions designated precedential or informative by the Patent Trial...more
Addressing issues related to patent eligibility, infringement, and damages, the US Court of Appeals for the Federal Circuit vacated in part, affirmed in part, and remanded, finding that certain result-oriented claims were...more
In addition to the briefs from the parties, seventeen amicus briefs were filed with the Supreme Court in Hikma v. Amarin: six in favor of Petitioner Hikma, seven in favor of Respondent Amarin, and the remaining five on behalf...more
We all like big numbers. A patent portfolio with hundreds or thousands of patents looks impressive on paper. It sounds good in pitch decks. It makes for nice PR....more
On April 16, 2026, the U.S. Court of Appeals for the Federal Circuit reversed the district court’s judgment as a matter of law (“JMOL”) finding Teva’s asserted patent claims invalid for lack of written description and...more
On April 10, 2026, the U.S. District Court for the Western District of Texas issued a split ruling in VE Opening LLC v. Sprinklr, Inc., No. 1:25-cv-01736-ADA, that underscores a critical lesson for patent owners and...more
TEVA PHARMACEUTICALS INTERNATIONAL GMBH v. ELI LILLY AND COMPANY - Before Prost, Cunningham, and Andrews. Appeal from the United States District Court of the District of Massachusetts. A functionally defined genus recited in...more
In Fortress Iron, LP v. Digger Specialties, Inc., the Federal Circuit affirmed summary judgment that two Fortress patents were invalid because they omitted a coinventor who could not be located and added under the...more
On April 29, the U.S. Supreme Court held oral arguments in the Hikma v. Amarin “skinny labeling” case, which considers the pleading standard for claims of “active inducement” of patent infringement when a generic drug is...more
Yesterday, the U.S. Supreme Court heard oral argument in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc., No. 24-889, a case that could reshape the landscape of pharmaceutical patent enforcement and generic drug...more
In recent years, the Federal Circuit has, with varying levels of agreement, considered what behavior by generic drugmakers constitutes inducement of infringement regarding so-called “off-label” prescribing for indications not...more
Key Takeaways - The USPTO has expanded design patent protection for digital and emerging technologies. Its March 2026 guidance confirms that graphical user interfaces (GUIs), icons, and designs in AR/VR, holograms and...more
VLSI TECHNOLOGY LLC v. INTEL CORP. - Before Moore, Chen, and Kleeh. Appeal from the United States District Court for the Northern District of California. The Federal Circuit reversed summary judgment of noninfringement by...more
DEFINITIVE HOLDINGS, LLC v. POWERTEQ LLC - Before Moore, Dyk, and Cunningham. Appeal from the United States District Court for the District of Utah. A third-party sale of a product embodying the claimed invention before the...more
Historically, some operating companies treated older patents in their portfolio as background assets—useful for defensive signaling, occasionally relevant in licensing discussions if a particular technology later found...more
In a significant decision for telecommunications patent law, a panel of the Federal Circuit issued a mixed ruling in Constellation Designs, LLC v. LG Electronics Inc, vacating a summary judgment of patent eligibility for...more
The opinion in Teva Pharms. Int’l GMBH v. Eli Lilly & Co., No. 24-1094 (Fed. Cir. April 16, 2026) creates a distinction for written description and enablement under 35 U.S.C. §112(a) when the claims in dispute are...more
The Federal Circuit recently clarified its written description jurisprudence concerning claims directed to methods of using a genus. Teva Pharms. Int’l GmbH v. Eli Lilly & Co., No. 24-1094, 2026 WL 1025802 (Fed. Cir. Apr. 16,...more
In the wake of the Federal Circuit’s 2024 Orange Book delisting decision in Teva v. Amneal, Hatch-Waxman practitioners have been left to grapple with several unanswered questions. Although the decision clarified what is...more
On March 18, 2026, the Court of Appeal of the Unified Patent Court (the UPC) dismissed an appeal over the protection of information. The UPC Court of Appeal confirmed its previous approach: there is no implicit limitation...more
ImagineAR, Inc., v. Niantic, Inc., 2026 WL 936029 (D. Del. Apr. 7, 2026) - Brushing aside a § 101 rejection overcome during the prosecution of U.S. Patent No. 10,946,284 (“the ’284 Patent”), District Judge Wolson granted...more